Source comparison
A Comparison: Tesamorelin vs. Other GHRH Peptides
To better contextualize tesamorelin's timeline and function, it's helpful to see how it stacks up against other popular GHRH analogues used in research, such as Sermorelin and CJC-1295. While they all aim to stimulate GH release, their structure and half-life
This comparison does not assign a generated winner or score.
- To better contextualize tesamorelin's timeline and function, it's helpful to see how it stacks up against other popular GHRH analogues used in research, such as Sermorelin and CJC-1295. While they all aim to stimulate GH release, their structure and half-life create different profiles.
- Structure
- 44 amino acid GHRH analogue
- First 29 amino acids of human GHRH
- 29 amino acid GHRH analogue (modified)
- Mechanism
- Potent GHRH receptor agonist
- GHRH receptor agonist
- Half-Life
- ~25-40 minutes
- ~10-12 minutes
- ~30 minutes
- Key Research Focus
- Significant reduction of visceral adipose tissue (VAT)
- General anti-aging, overall GH optimization
- GH optimization, often stacked with a GHRP
- As you can see, tesamorelin's longer chain and structure contribute to a slightly longer half-life and a more potent, specific action, particularly concerning VAT. Sermorelin, being a shorter fragment, provides a strong but more fleeting GH pulse. CJC 1295 NO DAC, also known as Mod GRF 1-29, is structurally modified for better stability and provides a similarly strong, natural GH pulse. The choice between them depends entirely on the specific goals of the research protocol.